Skip to content
Awesome – Lifestyle
Author:
Mira Pharmaceuticals, Inc.
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
September 17, 2026
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
September 1, 2026
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
August 6, 2026
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
July 30, 2026